Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
Publication
, Journal Article
Kirk, AD; Harlan, DM
Published in: Nature Medicine
February 2000
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nature Medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
February 2000
Volume
6
Issue
2
Start / End Page
114 / 114
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Immunology
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kirk, A. D., & Harlan, D. M. (2000). Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine, 6(2), 114–114. https://doi.org/10.1038/72164
Kirk, Allan D., and David M. Harlan. “Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.” Nature Medicine 6, no. 2 (February 2000): 114–114. https://doi.org/10.1038/72164.
Kirk AD, Harlan DM. Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine. 2000 Feb;6(2):114–114.
Kirk, Allan D., and David M. Harlan. “Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.” Nature Medicine, vol. 6, no. 2, Springer Science and Business Media LLC, Feb. 2000, pp. 114–114. Crossref, doi:10.1038/72164.
Kirk AD, Harlan DM. Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine. Springer Science and Business Media LLC; 2000 Feb;6(2):114–114.
Published In
Nature Medicine
DOI
EISSN
1546-170X
ISSN
1078-8956
Publication Date
February 2000
Volume
6
Issue
2
Start / End Page
114 / 114
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Immunology
- 11 Medical and Health Sciences